Speaker
Description
Background:Warfarin is the most widely used treatment in the prevention and treatment of blood clots. Its use is difficult due to the limited therapeutic range and the difference in response to the standard dose from one person to another. The metabolism of warfarin is controlled genetically primarily by the CYP2C9 gene, &by the VKORC1 gene. This study is the first of its kind in Iraq in identifying allelic genotypes CYP2C9 * 2, CYP2C9 * 3 -1639G VKORC1 and -1639A VKORC1 and determining the relationship between genetic and non-genetic factors with daily warfarin dose and adjust the dose of warfarin to reduce the side effects.
Methods: A cross sectional study was carried out on a sample of Iraqi patients from Baghdad city who were admitted to Ibn AL-Bitar Specialized Center for cardiac surgery. Blood samples of all patients were collected for both hematological and genetic analysis utilizing standard techniques.
Results: The frequency of CYP2C93 allele was 9.4% whereas that of CYP2C92 allele was 13.7%. The frequency of (VKORC1-1639G) allele was 58.75% and the frequency of (VKORC1-1639A) allele was 41.25%. Patients’ daily warfarin doses were administered according to their genotype. and non-genetic factors that include weight, height, age and sex, an equation was formed that enables us to calculate the warfarin dose for each person before starting treatment, which helps reduce side effects and reduces the error rate of giving the wrong dose.
Conclusion: It can be concluded that CYP2C93 and VKORC1 had significant effect on warfarin dose. New warfarin-dosing algorithm was developed based on CYP2C93 and VKORC1genotypes for predicting the required dose of warfarin.
| Has the manuscript been published? | Published |
|---|---|
| Intend to be published in the conference journal (IJPS)? | No |
| Field/discipline | Pharmacology & Toxicology |
